An observational study in COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19 and Pregnancy Related, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Charite University, Berlin, Germany · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in COVID-19 by Charite University, Berlin, Germany — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · Charite University, Berlin, Germany.
Among the 12 studies in COVID-19 by Charite University, Berlin, Germany, this one is the only one that started in 2025, is one of 7 observational ones, and was the 12th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →2 of the 12 studies in COVID-19 by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 111 across the 5 interventional studies, 750 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in COVID-19 by Charite University, Berlin, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to characterize patients in the Post-Intensive-Care-Syndrome (PICS) outpatient clinic based on routine data and to evaluate their treatment outcome over the course of their treatment. For this purpose, data sets from approx. 40 patients who were treated in the intensive care unit subsequently evaluated in the PICS outpatient clinic between March 27, 2020, and May 6, 2024, will be analyzed.
This is a retrospective comparison of approximately 13 pregnant patients and approximately 27 non-pregnant patients who developed respiratory failure (also known as acute respiratory distress syndrome, or ARDS) due to COVID-19 infection. The analysis is based on routine treatment data from the Post-Intensive Care Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), as well as intensive care treatment data, primarily from the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK). In some cases, additional data were obtained from the Medical Clinic for Nephrology and Internal Intensive Care Medicine (CCM/CVK/CBF), the Medical Clinic specializing in Hepatology and Gastroenterology (CCM/CVK), and the Department of Infectiology, Pulmonology, and Intensive Care Medicine (CCM).
Adult female pregnant and non-pregnant patients who were admitted to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine, Charité - Universitaetsmedizin Berlin between March 27, 2020 and May 6, 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Pregnancy at the time of initial hospital admission (not necessarily at the time of transfer to Charité - Universitätsmedizin Berlin). * Age: 18 years and older * Admission to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine between March 27, 2020 and May 6, 2024. * COVID-19 infection in temporal association with the intensive care unit admission. * Intensive care unit admission with lung failure or development of lung failure in the course of intensive care unit treatment. * Admission to the intensive care unit with lung failure or development of lung failure during intensive care unit stay
* No pregnancy at the time of admission. * Age: 18 years and older * Admission to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine between March 27, 2020 and May 6, 2024. * COVID-19 infection in temporal association with the intensive care unit admission. * Intensive care unit admission with lung failure or development of lung failure in the course of intensive care unit treatment. * Admission to the intensive care unit with lung failure or development of lung failure during intensive care unit stay
Impairment in at least one PICS domain (mobility, cognition, and/or mental health)
Impairment in at least one PICS domain (mobility, cognition, and/or mental health) after discharge from the ICU, assessed at the time of presentation to the PICS outpatient clinic. The planned PICS outpatient presentation takes place 3 and 6 months (ranging from 1 month to 3 years) after the initial ICU stay.
Time frame: 27.03.2020-06.05.2024
Catecholamine therapy
Catecholamine therapy during intensive care unit (ICU) treatment is measured in doses and duration.
Time frame: 27.03.2020-06.05.2024
Extracorporeal Membrane Oxygenation treatment
Extracorporeal Membrane Oxygenation treatment in the ICU Yes or No
Time frame: 27.03.2020-06.05.2024
Need for ventilation during ICU treatment
Need for ventilation during ICU treatment and, if so, ventilation route (non-invasive and invasive, endotracheal tube and tracheostomy tube) and duration of ventilation
Time frame: 27.03.2020-06.05.2024
Duration of ventilation during ICU treatment
Duration of ventilation during ICU treatment is measured in hours
Time frame: 27.03.2020-06.05.2024
Oxygenation index
Oxygenation index/Horowitz index is defined as the ratio of the arterial partial pressure of oxygen (PaO₂, in mmHg) to the fraction of inspired oxygen (FiO₂, expressed as a decimal).
Time frame: 27.03.2020-06.05.2024
Severity of illness
Severity of illness during ICU treatment is assessed with validated intensive care unit scores.
Time frame: 27.03.2020-06.05.2024
Incidence of delirium
Incidence of delirium in the ICU is measured with validated delirium scores.
Time frame: 27.03.2020-06.05.2024
Duration of delirium
Duration of delirium in the ICU is measured in days
Time frame: 27.03.2020-06.05.2024
Sedation Medications
Kind of medications required for sedation.
Time frame: 27.03.2020-06.05.2024
Sedation dosage
The amount of drug required for sedation.
Time frame: 27.03.2020-06.05.2024
Duration of sedation
Duration of sedation is measured in days.
Time frame: 27.03.2020-06.05.2024
Depth of sedation
Depth of sedation during ICU treatment
Time frame: 27.03.2020-06.05.2024
Continuous muscle relaxation
Continuous muscle relaxation during ICU treatment
Time frame: 27.03.2020-06.05.2024
Vaccination status
Vaccination status at the start of ICU treatment
Time frame: 27.03.2020-06.05.2024
COVID-19-specific immunotherapy
COVID-19-specific immunotherapy (e.g., tocilizumab, dexamethasone, baricitinib) during ICU treatment
Time frame: 27.03.2020-06.05.2024
Type of Anti-infective therapy
Type of anti-infective therapy during ICU treatment
Time frame: 27.03.2020-06.05.2024
Duration of Anti-infective therapy
Duration of anti-infective therapy during ICU treatment is measured in days.
Time frame: 27.03.2020-06.05.2024
Week of pregnancy
Week of pregnancy during ICU treatment in the pregnant women group
Time frame: 27.03.2020-06.05.2024
Need for a cesarean section
Need for a cesarean section in the pregnant women group, yes or no.
Time frame: 27.03.2020-06.05.2024
Organ complications
Organ complications, including bleeding and pregnancy complications during hospital treatment. Data from patient records.
Time frame: 27.03.2020-06.05.2024
Nutrition
Nutrition (enteral vs. parenteral) during ICU treatment
Time frame: 27.03.2020-06.05.2024
Dialysis 1
Dialysis during ICU treatment (binary)
Time frame: 27.03.2020-06.05.2024
Dialysis 2
Dialysis during ICU treatment (duration)
Time frame: 27.03.2020-06.05.2024
Intensive care unit mortality
Data from patient records
Time frame: 27.03.2020-06.05.2024
Hospital mortality
Data from patient records
Time frame: 27.03.2020-06.05.2024
90-day mortality
Data from patient records
Time frame: 27.03.2020-06.05.2024
180-day mortality
Data from patient records
Time frame: 27.03.2020-06.05.2024
Intensive care unit length of stay
Participants are followed up for the duration of intensive care unit stay, an expected average of 2 days
Time frame: 27.03.2020-06.05.2024
Duration of Hospital stay
Participants are followed up for the duration of hospital stay, an expected average of 7 days
Time frame: 27.03.2020-06.05.2024
Grip strength Test
Grip strength at the time of presentation to the PICS outpatient clinic is measured with a dynamometer.
Time frame: 27.03.2020-06.05.2024
Mobility
Mobility at the time of presentation to the PICS outpatient clinic is measured with the Timed Up-and-Go (TUG).
Time frame: 27.03.2020-06.05.2024
Cognition 1
Cognition 1 at the time of presentation to the PICS outpatient clinic is measured with the MiniCog. The MiniCog consists of two items, the word recall test and the clock-drawing test. Performance in these test is rated on a scale ranging from 0 - 5, with \<3 points indicating a suspicion of dementia.
Time frame: 27.03.2020-06.05.2024
Cognition 2
Cognition 2 at the time of presentation to the PICS outpatient clinic is measured with the Animal Naming Test
Time frame: 27.03.2020-06.05.2024
Mental health
Mental health at the time of presentation to the PICS outpatient clinic is measured with Patient Health Questionnaire-4 (It comprises the first two questions of the depression module of the PHQ-D \[PHQ-2\] and the first two questions of the module for assessing generalized anxiety \[GAD-2\]) and patient questionnaire with subjective patient assessment.
Time frame: 27.03.2020-06.05.2024
PBQ Parent-Child Relationship Questionnaire
PBQ at the time of presentation to the PICS outpatient clinic. This questionnaire is a 25-question self-completion questionnaire, which was developed in order to recognize disorders in the mother-child relationship at an early stage. The questionnaire is made up of 4 scales. Scale 1 Delayed attachment cut-off 12, Scale 2 Rejection and anger cut-off 17, Scale 3 Anxiety cut-off 10 and Scale 4 Risk of child abuse cut-off 3.
Time frame: 27.03.2020-06.05.2024
Edinburgh Postpartum Depression Questionnaire (EPDS)
The Edinburgh Postnatal Depression Scale (EDPS) was developed to identify women who may have postpartum depression. Each answer is given a score of 0 to 3 .The maximum score is 30. A score of more than 10 suggests minor or major depression may be present.
Time frame: 27.03.2020-06.05.2024
Health-related quality of life
Health-related quality of life at the time of presentation to the PICS outpatient clinic is measured with EQ-5D-5L questionnaire. Higher Score indicate better Healt-related quality of life.
Time frame: 27.03.2020-06.05.2024
Started Sep 2025 (actual). Primary completion is estimated for Jun 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →